Not provided
Not provided
Not provided
Not provided
Not provided
Administrative reasons
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
EPIFLO® unit along with standard wound care vs only standard wound care for Surgical site infections (SSI).
Surgical site infections (SSI) after instrumented spinal fusions are not rare, and patients with SSI after instrumented spinal surgery often require repeat operations and prolonged intravenous antibiotic therapy. Wound hypoxia has been identified as a pathogenic mechanism behind wound infection and poor healing. Transdermal oxygen delivery (EPIFLO) has recently become a novel strategy to facilitate wound healing.
The study doctor will give an EPIFLO® unit along with standard wound care to some subjects in this study to see if it is safe and can help them. Another purpose of this study is to find out if using EPIFLO® is better than getting only standard wound care for Surgical site infections (SSI). The sponsor also wants to compare the cost of using the study device and standard wound care to the cost of standard wound care alone. The U.S. Food and Drug Administration (FDA) has approved EPIFLO® to treat skin ulcers (including diabetic skin ulcers), bedsores, amputations, skin grafts, burns, and frostbite.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transdermal Continuous Oxygen Therapy | Experimental | EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care |
|
| Standard of care | No Intervention | standard wound care for 2 weeks |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EPIFLO | Device | Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of surgical site infection | The primary objective of this study is to assess surgical site infection within 3 months of surgery for "high risk" patients undergoing posterior cervical, posterior thoracic, or posterior lumbar instrumented spinal fusions in patients receiving adjunct Transdermal Continuous Oxygen therapy vs. standard of care control. Surgical site infection will be clinically assessed by the PI according to CDC criteria. Independent blinded assessment by a clinician blinded to the allocation arm will also be obtained. The number of patients with infection (and the severity of infection) in the treated arm will be compared to the number in the control arm. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Resource utilization | Resource utilization- the sum total of cost of treatments, hospital stays, bandages, nursing care and anything else related to treatment all measured in dollar amounts and then summed | 3 months |
| Severity of infection |
Not provided
Inclusion Criteria:
Elective spinal fusion - posterior cervical, posterior thoracic, or posterior lumbar instrumented spinal fusions
Patient Age 18-80
Patients must be considered high risk for infection, meeting one or more of the following criteria:
Exclusion Criteria:
Major Study Exclusion Criteria include:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nestor Tomycz, M.D. | Department of Neurosurgery | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Neurological Surgery Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The outcomes assessor will be given blinded data and pictures to enable unbiased assessment.
|
|
Severity of infection - Superficial or deep as per CDC classification as assessed by investigator
| 3 months |